Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 52.97% is 134% above its 5-year average of -154.57%, near the high end of its 5-year range (-905.08%–103.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.18% below its 12-month average of 78.10%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 52.97%.
RETURN ON EQUITY (ROE)
52.97%
RETURN ON EQUITY (ROE) AVG TTM
78.10%
RETURN ON EQUITY (ROE) AVG 3Y
-249.62%
RETURN ON EQUITY (ROE) AVG 5Y
-154.57%
RETURN ON EQUITY (ROE) AVG 10Y
-48.95%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-32.18%
CURRENT VS 3Y AVG
+121.22%
CURRENT VS 5Y AVG
+134.27%
CURRENT VS 10Y AVG
+208.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-19.35%
median of 259 covered companies
CURRENT VS SECTOR MEDIAN
+373.75%
vs the sector median at left
Ascendis Pharma A/S
Market Cap
$14.16B
Return on Equity (ROE)
52.97%
TTM Avg
78.10%
3Y Avg
-249.62%
5Y Avg
-154.57%
Market Cap
$14.64B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
Market Cap
$14.79B
Return on Equity (ROE)
46.68%
TTM Avg
29.72%
3Y Avg
22.87%
5Y Avg
17.28%
Market Cap
$14.97B
Return on Equity (ROE)
-8.40%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
Market Cap
$13.19B
Return on Equity (ROE)
7.78%
TTM Avg
17.97%
3Y Avg
19.27%
5Y Avg
21.22%
Market Cap
$15.24B
Return on Equity (ROE)
29.88%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$12.95B
Return on Equity (ROE)
N/A
TTM Avg
35.81%
3Y Avg
39.37%
5Y Avg
-92.14%
Market Cap
$12.89B
Return on Equity (ROE)
3.51%
TTM Avg
5.40%
3Y Avg
5.85%
5Y Avg
7.17%
Market Cap
$12.52B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 52.97% | 78.10% | -249.62% | -154.57% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -57.18% | -651.33% | -315.37% | -198.08% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 46.68% | 29.72% | 22.87% | 17.28% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | -8.40% | -2.13% | 6.32% | 9.65% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 7.78% | 17.97% | 19.27% | 21.22% |
| Solventum Corporation (SOLV)vs › | $15.24B | 29.88% | 23.51% | 17.50% | 13.68% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | 35.81% | 39.37% | -92.14% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 3.51% | 5.40% | 5.85% | 7.17% |
| Baxter International Inc. (BAX)vs › | $12.52B | -17.13% | -12.46% | -8.76% | -1.37% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 10.49% | 6.83% | 5.29% | 3.21% |
ROE
53.0%
ROA
33.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 52.97% |
| 2026-03-31 | 103.24% |
| 2023-06-30 | -905.08% |
| 2023-03-31 | -327.12% |
| 2022-12-31 | -217.07% |
| 2022-09-30 | -115.35% |
| 2022-06-30 | -68.71% |
| 2022-03-31 | -68.76% |
| 2021-12-31 | -44.41% |
| 2021-09-30 | -43.10% |
| 2021-06-30 | -66.91% |
| 2021-03-31 | -52.32% |
| 2020-12-31 | -47.72% |
| 2020-09-30 | -36.71% |
| 2020-06-30 | -54.86% |
| 2020-03-31 | -42.02% |
| 2019-12-31 | -36.51% |
| 2019-09-30 | -26.53% |
| 2019-06-30 | -26.47% |
| 2019-03-31 | -20.25% |
| 2018-12-31 | -47.92% |
| 2018-09-30 | -44.77% |
| 2018-06-30 | -40.87% |
| 2018-03-31 | -39.03% |
| 2017-12-31 | -63.58% |
| 2017-09-30 | -49.91% |
| 2017-06-30 | -69.02% |
| 2017-03-31 | -48.09% |
| 2016-12-31 | -40.86% |
| 2016-09-30 | -85.71% |
| 2016-06-30 | -58.73% |
| 2016-03-31 | -52.87% |
| 2015-12-31 | -27.87% |
| 2015-09-30 | -20.04% |
| 2015-06-30 | -15.76% |
| 2015-03-31 | -6.24% |
| 2014-12-31 | -22.04% |
| 2014-09-30 | -95.49% |
| 2014-06-30 | 8.04% |
| 2014-03-31 | 47.31% |
| 2013-12-31 | 63.42% |
